Navigation Links
Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Melanoma Cancer Clinical Trial
Date:9/24/2009

CALGARY, Sept. 24 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) announced today that the Cancer Therapy Research Center at the University of Texas Health Science Center (CTRC) has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with metastatic melanoma. The Principal Investigator is Dr. Devalingam Mahalingam, M.D., Ph.D., MRCP(UK), MRCP(I), clinical investigator in GI/thoracic oncology and drug development at the CTRC.

"We have seen some very encouraging results in our clinical trials using REOLYSIN in combination with other therapies in metastatic melanoma patients," said Dr. Brad Thompson, President and CEO of Oncolytics. "For example, of nine evaluable melanoma patients treated intravenously in our combination REOLYSIN and chemotherapy trials, five had stable disease or better (two partial responses and three stable disease).

"In our local administration REOLYSIN and radiation studies, all of the evaluable melanoma patients (10) had stable disease or better in the target lesion, (three partial responses, one significant minor response and six stable disease). These results, combined with preclinical work demonstrating that in vivo combination treatment resulted in markedly reduced tumour growth compared to single agent treatments, provided the rationale for our collaborators to explore a Phase 2 combination study for patients with metastatic melanoma."

"Today, few effective treatment options exist for patients with advanced malignant melanoma," said Dr. Mahalingam. "We welcome this collaboration with Oncolytics, and are excited to have started patient enrolment for this Phase II investigator-initiated study at the CTRC. We are hopeful this no
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Oncolytics Biotech Inc. Announces Start of Patient Enrolment in Translational Clinical Trial Investigating REOLYSIN(R) in Patients with Metastatic Colorectal Cancer
2. Cancer Therapy & Research Center at The University of Texas Health Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial Clinical Research Collaboration
3. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
4. Oncolytics Biotech(R) Inc. Announces Publication of Research on Synergistic Activity of Reovirus and Chemotherapy in NSCLC
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014  Luminex Corporation (Nasdaq: LMNX ... for the fourth quarter of 2013 on Monday, February ... scheduled for release after the close of trading. ... will hold a conference call to discuss the operating ... twelve months ended December 31, 2013 on February 3, ...
(Date:1/14/2014)... HARRISBURG, Pa. , Jan. 14, 2014 Dynamic ... LLC ("GMH"), announced today that it acquired Progressive Home Medical ... on January 7, 2014. The terms of the acquisition were ... durable medical equipment ("DME") company providing a wide range of ... Pennsylvania and Pittsburgh ...
(Date:1/14/2014)... Minn. , Jan. 14, 2014   NuAire , ... research, have come to agreement with Hitachi Koki ... the Hitachi brand of centrifuges in North America ... throughout the United States and ... product benefits and features, options and accessories, training, pricing, as ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
... risk factors such as high blood sugar and insulin, ... before pregnancy, predict whether a woman will develop diabetes ... study in the current issue of the American ... suggests that metabolic screening of all women before ...
... Texas, Oct. 12 Lexicon Pharmaceuticals, Inc. (Nasdaq: ... breakthrough treatments for human disease, announced today that Dr. ... present at the upcoming BioCentury Newsmakers in the Biotech Industry ... 10:30 a.m. Eastern Time. A live webcast of ...
Cached Medicine Technology:Metabolic Status Before Pregnancy Predicts Subsequent Gestational Diabetes 2Metabolic Status Before Pregnancy Predicts Subsequent Gestational Diabetes 3Metabolic Status Before Pregnancy Predicts Subsequent Gestational Diabetes 4Metabolic Status Before Pregnancy Predicts Subsequent Gestational Diabetes 5Lexicon Pharmaceuticals to Present at BioCentury Newsmakers in the Biotech Industry Conference Oct. 22nd 2
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... By Serena Gordon HealthDay Reporter , MONDAY, May ... with a normal, healthy weight, already have one or more ... 22 percent of today,s teens have borderline-high or already high ... have pre-diabetes or diabetes, according to the new research based ...
... HealthDay Reporter , MONDAY, May 21 (HealthDay News) -- In a ... high decibels on their MP3 players were also more likely than ... at concerts and clubs were more likely to drink heavily and ... don,t prove that loud music or concerts have anything to do ...
... tuberculosis vaccine is often used as a treatment for ... vaccine,s effectiveness, according to new research from the University ... Urological Association annual meeting. , Yi-Fen Lee, Ph.D., associate ... study in a mouse model showing that a combination ...
... May 21 (HealthDay News) -- Having so-called intensivist physicians on ... death rates in ICUs that do not have similar coverage ... An intensivist is a doctor who specializes in the care ... or co-manage patients during the day are referred to as ...
... in Spanish . Flexible sigmoidoscopy, a ... has fewer side effects than colonoscopy, is effective in reducing ... cancer, according to research sponsored by the National Cancer Institute, ... study that spanned almost 20 years, researchers found that overall ...
... Multiple research projects including a 2006 study ... Hill have used DNA microarray analysis to identify ... basal-like and HER2-enriched. Simple tests are being developed to ... patients in a more biologically-based way. In turn, these ...
Cached Medicine News:Health News:U.S. Teens Heading for Heart Trouble: Study 2Health News:U.S. Teens Heading for Heart Trouble: Study 3Health News:Teens' Love of Loud Music Tied to Drinking, Drug Abuse 2Health News:Vitamin D + TB vaccine: Allies in fight against bladder cancer? 2Health News:Night Staffing With Critical Care Docs May Lower ICU Death Rates 2Health News:NIH study finds sigmoidoscopy reduces colorectal cancer rates 2Health News:NIH study finds sigmoidoscopy reduces colorectal cancer rates 3Health News:NIH study finds sigmoidoscopy reduces colorectal cancer rates 4Health News:Discovery suggests new combination therapy strategy for basal-like breast cancers 2
Tennant angled tying forceps with extra delicate smooth jaws, 6 mm tying platform, For 9-0 to 11-0 sutures. Overall length 108 mm....
Catalano curved tying forcep has 6 mm V-grove tying platform. Overall length 100 mm....
Kelman - McPherson angled tying forceps is long with tying platform 10 mm, serrated handle and polished finish....
Suture tying forceps (S&T) is straight, 13.5 cm long, flat handle, 9 mm wide, tip diameter 0.3 mm with tying platform....
Medicine Products: